Which is better, HAE or SRPT?

On the Buffett-Fit framework, Haemonetics Corporation (HAE) currently grades higher than SRPT — 70/100 (B grade) vs 40/100 (D). That said, "better" depends on which framework you trust — HAE wins on Warren Buffett, Benjamin Graham, Philip Fisher, Joel Greenblatt, Charlie Munger, and Terry Smith; SRPT wins on Peter Lynch. The full pillar breakdown is on this page.

Should I buy HAE or SRPT?

This page is an educational comparison, not investment advice. Both HAE and SRPT are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is HAE better than SRPT for value investing?

On the Buffett-style value-investing framework, HAE currently grades higher — 70/100 vs 40/100, a 30-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between HAE and SRPT on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). HAE currently scores 70/100 (B grade); SRPT scores 40/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, HAE or SRPT?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. HAE and SRPT are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, HAE or SRPT?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are HAE and SRPT both Healthcare stocks?

Yes — both Haemonetics Corporation (HAE) and Sarepta Therapeutics, Inc. (SRPT) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this HAE vs SRPT comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Haemonetics

Sarepta Therapeutics

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

HAE

Haemonetics

Market cap

$2.98B

Sector

Healthcare

SRPT

Sarepta Therapeutics

Market cap

$1.77B

Sector

Healthcare

Overall winner

Haemonetics HAE

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	HAE	SRPT	Winner
Warren Buffett	70B	40D	HAE
Benjamin Graham	85A	47D	HAE
Philip Fisher	60C	51C	HAE
Peter Lynch	54C	59C	SRPT
Joel Greenblatt	31F	7F	HAE
Charlie Munger	54D	39D	HAE
Terry Smith	55D	33F	HAE

Side-by-side metrics

Metric	HAE	SRPT
Market cap	$2.98B	$1.77B
P/E (TTM)	24.8x	31.3x
EV/EBIT	14.1x	-
ROIC (TTM)	8.37%	-1.53%
Gross margin	55.74%	62.39%
Net margin	7.29%	2.98%
Revenue CAGR 5y	7.65%	33.03%
EPS CAGR 5y	24.62%	-
Debt / Equity	1.5x	0.7x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HAE leads on

ROIC (TTM)8.37%vs -1.53%+118%
Net margin7.29%vs 2.98%+59%
Market cap$2.98Bvs $1.77B+40%
P/E (TTM)24.8xvs 31.3x+21%

SRPT leads on

EV/EBIT-vs 14.1x+128%
Revenue CAGR 5y33.03%vs 7.65%+77%
Debt / Equity0.7xvs 1.5x+55%
Gross margin62.39%vs 55.74%+11%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Haemonetics

Sarepta Therapeutics

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like HAE

More like SRPT

Related on invest-like

Key terms in this analysis